RxDoctor Payments Data

Rachel Easterwood

Women's Health · Dalton, GANPI 1053913160

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $973, 8.9 times the $109 reported in 2021.

$1,855in general payments, 2019–2025

Across 84 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$397
  • Mayne Pharma Commercial LLC$285
  • Astellas Pharma US Inc$253
  • Lilly USA, LLC$224
  • Sumitomo Pharma America, Inc.$193
  • Takeda Pharmaceuticals U.S.A., Inc.$174
  • plus $328 from 9 others

What the payments were for

  • Food & beverage$1,855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,855 in reported general payments places this provider in the 85th percentile of 247 women's health providers in Georgia.

See all women's health providers in Georgia

Medicare billing

Part B allowed, 2024
$3,756
Medicare patients
19
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$42,397
TrintellixVortioxetine Hydrobromide12$5,760
Estradiol48$3,713
Estradiol (Once Weekly)Estradiol24$2,113
ProgesteroneProgesterone, Micronized33$1,938
Hydroxyzine Hcl18$272
Bupropion Hcl SrBupropion Hcl13$98
Metformin Hcl12$87
Levothyroxine Sodium13$75
Amitriptyline Hcl11$52
Medroxyprogesterone Acetate12$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$224$42,39740 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$174$5,76012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 women's health providers in Georgia.

Other women's health in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →